Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Haohai Biological Technology Co (FRA:5HB) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Shanghai Haohai Biological Technology Co Forward PE Ratio Related Terms
Shanghai Haohai Biological Technology Co Forward PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Haohai Biological Technology Co Forward PE Ratio Chart
Shanghai Haohai Biological Technology Co Annual Data
Trend
2021-12
2022-12
2023-12
2024-12
2025-12
Forward PE Ratio
12.24
13.30
13.62
10.22
9.28
Shanghai Haohai Biological Technology Co Quarterly Data
2021-12
2022-06
2022-09
2022-12
2023-03
2023-06
2023-09
2023-12
2024-12
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
12.24
12.94
9.01
13.30
14.47
11.66
14.60
13.62
10.22
9.43
8.66
9.28
8.41
FRA:5HB vs VRTX, REGN, RVMD: Forward PE Ratio Comparison
For the Biotechnology subindustry, Shanghai Haohai Biological Technology Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Haohai Biological Technology Co Forward PE Ratio vs Biotechnology Industry
Shanghai Haohai Biological Technology Co Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Shanghai Haohai Biological Technology Co (FRA:5HB) has a Forward PE Ratio of 5.63 as of Aug. 01, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Shanghai Haohai Biological Technology Co and its competitors. According to the industry distribution chart, Shanghai Haohai Biological Technology Co ranks #61 out of 354 companies in the Biotechnology industry, placing it in the top 17.2%.
Is Shanghai Haohai Biological Technology Co's Forward PE Ratio too high?
Shanghai Haohai Biological Technology Co's current Forward PE Ratio is 5.63. The Biotechnology industry median Forward PE Ratio is 22.53. Shanghai Haohai Biological Technology Co's value of 5.63 is 75% below this industry median. Based on the distribution chart, Shanghai Haohai Biological Technology Co ranks #61 out of 354 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Haohai Biological Technology Co has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Haohai Biological Technology Co's Forward PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Haohai Biological Technology Co ranks #61 out of 354 companies for Forward PE Ratio. This places Shanghai Haohai Biological Technology Co in the top 17% of its industry — outperforming the majority of peers. The industry median Forward PE Ratio is 22.53. Shanghai Haohai Biological Technology Co's value of 5.63 is 75% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.53, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Haohai Biological Technology Co's current Forward PE Ratio of 5.63 is 75% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Shanghai Haohai Biological Technology Co and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Haohai Biological Technology Co's current Forward PE Ratio is 5.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Haohai Biological Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co (FRA:5HB) is currently considered Significantly Undervalued. The stock's GF Value™ is €2.69, compared to a current price of €1.78 — trading 33.8% below its estimated fair value. The current Forward PE Ratio is 5.63 and 75% below the Biotechnology industry median of 22.53. Shanghai Haohai Biological Technology Co's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Shanghai Haohai Biological Technology Co (FRA:5HB), the current Forward PE Ratio is 5.63 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Haohai Biological Technology Co (FRA:5HB) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co stock appears to be undervalued.
The current stock price of €1.78 is trading 33.8% below its estimated GF Value™ of €2.69.
GuruFocus considers Shanghai Haohai Biological Technology Co to be Significantly Undervalued.
Key valuation signals for FRA:5HB:
Forward PE Ratio: 5.63
GF Value™: €2.69 vs. price of €1.78 (33.8% below fair value)
Industry Position: 75% below the Biotechnology median (#61 of 354)
No single metric tells the full story. See the FRA:5HB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to a single operating segment, which is the manufacture and sale of biologicals, medical hyaluronate, and intraocular lenses, research and development of biological engineering and pharmaceutical products, and the provision of related services. Its products are categorized into four types, comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China, which is the key revenue driver, the United States, the United Kingdom, and other countries.
66GF Score
Get the complete analysis for FRA:5HB
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5HB has been successfully added to your 
